OxLDL causes both epigenetic modification and signaling regulation on the microRNA-29b gene: Novel mechanisms for cardiovascular diseases

Journal of Molecular and Cellular Cardiology

Volumn 52, Issue 3, 2012, Pages 587-595

  Chen, Ku Chung ^a,b   Liao, Yi Chu ^b,c,d   Hsieh, I Chung ^b   Wang, Yung Song ^a,b   Hu, Ching Yu ^a   Juo, Suh Hang Hank ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

AP 1; Atherosclerosis; Histone modification; MiR 29b; OxLDL

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CALCIUM CHELATING AGENT; CALCIUM ION; DNA; HISTONE DEACETYLASE 1; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; PROTEIN HISTONE 3 LYSINE 4; PROTEIN HISTONE 3 LYSINE 9; PROTEIN MICRORNA 29B; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME 1; CHROMOSOME 7; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; DOWN REGULATION; EPIGENETICS; GENE; GENE ACTIVATION; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE LOCATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; MICRORNA 29A GENE; MICRORNA 29B 1 GENE; MICRORNA 29B GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ACETYLATION; ANIMALS; CARDIOVASCULAR DISEASES; CELLS, CULTURED; ENZYME ACTIVATION; EPIGENESIS, GENETIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HISTONE DEACETYLASE 1; HISTONES; HUMANS; LIPOPROTEINS, LDL; METHYLATION; MICE; MICE, INBRED C57BL; MICRORNAS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-FOS; REACTIVE OXYGEN SPECIES; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION;

MUS;

EID: 84862791919     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.12.005     Document Type: Article

References (33)

1. Maziere C., Maziere J.C. Activation of transcription factors and gene expression by oxidized low-density lipoprotein. Free Radic Biol Med 2009, 46(2):127-137.
2. Fraga M.F., Ballestar E., Paz M.F., Ropero S., Setien F., Ballestar M.L., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 2005, 102(30):10604-10609.
3. Bannister A.J., Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011, 21(3):381-395.
4. de Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370(Pt 3):737-749.
5. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: what are the cancer relevant targets?. Cancer Lett 2009, 277(1):8-21.
6. Dje N'Guessan P., Riediger F., Vardarova K., Scharf S., Eitel J., Opitz B., et al. Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 2009, 29(3):380-386.
7. Yan Z.Q., Yao Q.P., Zhang M.L., Qi Y.X., Guo Z.Y., Shen B.R., et al. Histone deacetylases modulate vascular smooth muscle cell migration induced by cyclic mechanical strain. J Biomech 2009, 42(7):945-948.
8. Schickel R., Boyerinas B., Park S.M., Peter M.E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008, 27(45):5959-5974.
9. van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006, 103(48):18255-18260.
10. Liu X.Q., Ntambi J.M. Atherosclerosis: keep your macrophages in shape. Nat Med 2009, 15(12):1357-1358.
11. Chen K.C., Wang Y.S., Hu C.Y., Chang W.C., Liao Y.C., Dai C.Y., et al. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J 2011, 25(5):1718-1728.
12. Boon R.A., Seeger T., Heydt S., Fischer A., Hergenreider E., Horrevoets A.J., et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 2011.
13. Heinemeyer T., Wingender E., Reuter I., Hermjakob H., Kel A.E., Kel O.V., et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998, 26(1):362-367.
14. Boyes J., Byfield P., Nakatani Y., Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998, 396(6711):594-598.
15. Ruminy P., Gangneux C., Claeyssens S., Scotte M., Daveau M., Salier J.P. Gene transcription in hepatocytes during the acute phase of a systemic inflammation: from transcription factors to target genes. Inflamm Res 2001, 50(8):383-390.
16. Mott J.L., Kurita S., Cazanave S.C., Bronk S.F., Werneburg N.W., Fernandez-Zapico M.E. Transcriptional suppression of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J Cell Biochem 2010, 110(5):1155-1164.
17. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 1995, 270(28):16483-16486.
18. Chakraborti S., Chakraborti T. Oxidant-mediated activation of mitogen-activated protein kinases and nuclear transcription factors in the cardiovascular system: a brief overview. Cell Signal 1998, 10(10):675-683.
19. Ando K., Fujita T. Role of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in the development of hypertensive organ damage. Clin Exp Nephrol 2004, 8(3):178-182.
20. Fabbri M., Calin G.A. Epigenetics and miRNAs in human cancer. Adv Genet 2010, 70:87-99.
21. Lemasson I., Polakowski N.J., Laybourn P.J., Nyborg J.K. Transcription factor binding and histone modifications on the integrated proviral promoter in human T-cell leukemia virus-I-infected T-cells. J Biol Chem 2002, 277(51):49459-49465.
22. Lennartsson A., Ekwall K. Histone modification patterns and epigenetic codes. Biochim Biophys Acta 2009, 1790(9):863-868.
23. Vesely P.W., Staber P.B., Hoefler G., Kenner L. Translational regulation mechanisms of AP-1 proteins. Mutat Res 2009, 682(1):7-12.
24. Chen B., Guan D., Cui Z.J., Wang X., Shen X. Thioredoxin 1 downregulates MCP-1 secretion and expression in human endothelial cells by suppressing nuclear translocation of activator protein 1 and redox factor-1. Am J Physiol Cell Physiol 2010, 298(5):C1170-C1179.
25. Wang H.H., Hsieh H.L., Wu C.Y., Sun C.C., Yang C.M. Oxidized low-density lipoprotein induces matrix metalloproteinase-9 expression via a p42/p44 and JNK-dependent AP-1 pathway in brain astrocytes. Glia 2009, 57(1):24-38.
26. Zhou B., Margariti A., Zeng L., Xu Q. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis. Cardiovasc Res 2011, 90(3):413-420.
27. Jung S.B., Kim C.S., Naqvi A., Yamamori T., Mattagajasingh I., Hoffman T.A., et al. Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ Res 2010, 107(7):877-887.
28. Findeisen H.M., Gizard F., Zhao Y., Qing H., Heywood E.B., Jones K.L., et al. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol 2011, 31(4):851-860.
29. Zhang J., Yang Y., Yang T., Liu Y., Li A., Fu S., et al. microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer 2010, 103(8):1215-1220.
30. Scott G.K., Mattie M.D., Berger C.E., Benz S.C., Benz C.C. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res 2006, 66(3):1277-1281.
31. Colussi C., Illi B., Rosati J., Spallotta F., Farsetti A., Grasselli A., et al. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment. Pharmacol Res 2010, 62(1):3-10.
32. Karlic R., Chung H.R., Lasserre J., Vlahovicek K., Vingron M. Histone modification levels are predictive for gene expression. Proc Natl Acad Sci U S A 2010, 107(7):2926-2931.
33. Jin W., Chen L., Chen Y., Xu S.G., Di G.H., Yin W.J., et al. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer. Breast Cancer Res Treat 2010, 123(2):359-373.